Advertisement

Cytokine levels predict 30-day mortality in octogenarians and nonagenarians with community-acquired pneumonia: a retrospective observational study

  • Héctor Pinargote-CelorioEmail author
  • Gemma Miralles
  • Miguel Cano
  • Esther Caparros
  • Joaquín Portilla
  • Gregorio González-Alcaide
  • José M. Ramos_Rincón
Original Article
  • 15 Downloads

Abstract

To analyze the value of cytokines (tumor necrosis factor [TNF]-α, interleukin [IL]-1β, IL-6, IL-8, IL-10) as predictors of mortality at 30 days in octogenarians and nonagenarians hospitalized in an internal medicine unit for community-acquired pneumonia (CAP). An observational, analytical, retrospective cohort study was conducted in the Department of Internal Medicine at Alicante General University Hospital between January 2014 and December 2015. Blood samples were frozen at − 80 °C, and cytokines were measured by ELISA. We included 115 patients, of whom 54% were men, with a mean age of 86.4 (standard deviation 4.5) years. There is a moderate correlation between IL-10 levels and CURB-65 score (p < 0.001) and a weak correlation with creatinine levels (p = 0.012) and urea levels (p = 0.032). Forty-five (39.1%) patients died within 30 days. In a multivariate analysis, the variables associated with mortality at 30 days were the following: age (adjusted odds ratio [ORa] 1.134, 95% confidence interval [CI] 1.02, 1.26), male sex (ORa 2.85, 95% CI 1.14, 7.14), IL-8 of 19 pg/mL or more (ORa 4.09, 95% CI 1.67, 10.01), and IL-10 of 11.29 pg/mL or more (ORa 4.00, 95% CI 1.58, 10.12). High IL-8 and IL-10 levels were shown to predict 30-day mortality in elderly patients with CAP. The inflammatory response in these patients seems to condition their prognosis. Further research in this line would provide more understanding about the physiopathological mechanisms and potential therapeutic targets for improving survival.

Keywords

Community acquired pneumonia Interleukin-8 Interleukin-10 Mortality Aged 80 and over 

Notes

Acknowledgments

The authors acknowledge our gratitude to all the patients who participated in this study.

Author contributions

H.P. collected the data and wrote the manuscript.

G.M. performed the immunology procedures and wrote the manuscript.

M.C., and E.C. performed the immunology procedures.

J.P. designed the study and wrote the manuscript.

J.M.R. designed the study, collected the data, and wrote the manuscript.;

H.P., G.M., M.C., E.C., J.P., G.G., and J.M.R. critically revised the intellectual content of the manuscript.

Funding

This study was supported by a grant (NI-13/2012) from Research Foundation of the General University Hospital of Alicante [Fundación para la Investigación del Hospital General Universitario de Alicante] and a grant (UGP-14-272) from the Foundation for promoting Health and Biomedical Research in the Valencian Region [Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana] (FISABIO)-ALICANTE.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethics approval

The Research Ethics Committee of General University Hospital of Alicante (Spain) approved the study.

Informed consent

We obtained written informed consent from each patient for study inclusion and for the voluntary donation of research biospecimens to the biobank.

References

  1. 1.
    Niu W-Y, Wan Y-G, Li M-Y, Wu Z-X, Zhang L-G, Wang J-X (2013) The diagnostic value of serum procalcitonin, IL-10 and C-reactive protein in community acquired pneumonia and tuberculosis. Eur Rev Med Pharmacol Sci 17:3329–3333PubMedGoogle Scholar
  2. 2.
    File TM (2019) Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults. In: Bartlett JG, Ramirez JA, editors. UpToDate. Waltham, Mass: UpToDate Inc; 2019.Google Scholar
  3. 3.
    Gutiérrez F, Masiá M, Rodríguez JC, Mirete C, Soldán B, Padilla S, et al (2005) Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol.Infect 11:788-800.  https://doi.org/10.1111/j.1469-0691.2005.01226.x CrossRefGoogle Scholar
  4. 4.
    Ramos JM, Sánchez-Martínez R, Nieto F, Sastre J, Valero B, Priego M et al (2016) Sex and age differences of patients admitted to General Internal Medicine Ward in Spain: a cross-sectional retrospective study of 13 years. Acta Medica Mediterr 32:273–284.  https://doi.org/10.19193/0393-6384_2016_2_41 CrossRefGoogle Scholar
  5. 5.
    Cilloniz C, Ceccato A, San Jose A, Torres A (2016) Clinical management of community acquired pneumonia in the elderly patient. Expert Rev Respir Med 1(10):1211–1220.  https://doi.org/10.1080/17476348.2016.1240037 CrossRefGoogle Scholar
  6. 6.
    Rea IM, Gibson DS, McGilligan V, McNerlan SE, Alexander HD, Ross OA (2018) Age and age-related diseases: role of inflammation triggers and cytokines. Front Immunol 9(9):586.  https://doi.org/10.3389/fimmu.2018.00586 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Romero-Cabrera ÁJ, Amores-Hernández L (2013) Casteleiro EF-. Inmunosenescencia y fragilidad: una mirada actual. Med Interna México 29:605–611Google Scholar
  8. 8.
    Hazeldine J, Lord JM (2015) Innate immunesenescence: underlying mechanisms and clinical relevance. Biogerontology 10(16):187–201.  https://doi.org/10.1007/s10522-014-9514-3 CrossRefGoogle Scholar
  9. 9.
    Janesch P, Stulik L, Rouha H, Varga C, Steinhäuser J, Zerbs M et al (2018) Age-related changes in the levels and kinetics of pulmonary cytokine and chemokine responses to Streptococcuspneumoniae in mouse pneumonia models. Cytokine 111:389–397.  https://doi.org/10.1016/j.cyto.2018.09.012 CrossRefPubMedGoogle Scholar
  10. 10.
    Bacci MR, Leme RCP, Zing NPC, Murad N, Adami F, Hinnig PF et al (2015) IL-6 and TNF-α serum levels are associated with early death in community-acquired pneumonia patients. Brazilian J Med Biol Res 48:427–432.  https://doi.org/10.1590/1414-431X20144402 CrossRefGoogle Scholar
  11. 11.
    Palomino DCT, Marti LC (2015) Chemokines and immunity. Einstein (Sao Paulo) 13:469–473.  https://doi.org/10.1590/S1679-45082015RB3438 CrossRefGoogle Scholar
  12. 12.
    Kutz A, Grolimund E, Christ-Crain M, Thomann R, Falconnier C, Hoess C et al (2014) Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients. BMC Anesthesiol 15(14):102.  https://doi.org/10.1186/1471-2253-14-102 CrossRefGoogle Scholar
  13. 13.
    Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR et al (2007) Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of Sepsis (GenIMS) study. Arch Intern Med 167:1655–1663.  https://doi.org/10.1001/archinte.167.15.1655 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Siljan WW, Holter JC, Nymo SH, Husebye E, Ueland T, Aukrust P et al (2018) Cytokine responses, microbial aetiology and short-term outcome in community-acquired pneumonia. Eur J Clin Investig 48:e12865.  https://doi.org/10.1111/eci.12865 CrossRefGoogle Scholar
  15. 15.
    Chen J-H, Chang S-S, Liu JJ, Chan R-C, Wu J-Y, Wang W-C et al (2010) Comparison of clinical characteristics and performance of pneumonia severity score and CURB-65 among younger adults, elderly and very old subjects. Thorax 1(65):971–977.  https://doi.org/10.1136/thx.2009.129627 CrossRefGoogle Scholar
  16. 16.
    Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD et al (2001) Guidelines for the management of adults with community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–1754.  https://doi.org/10.1164/ajrccm.163.7.at1010 CrossRefPubMedGoogle Scholar
  17. 17.
    Cillóniz C, Polverino E, Ewig S, Aliberti S, Gabarrús A, Menéndez R et al (2013) Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 144:999–1007.  https://doi.org/10.1378/chest.13-0062 CrossRefPubMedGoogle Scholar
  18. 18.
    Saldías Peñafiel F, O’Brien Solar A, Gederlini Gollerino A, Farías Gontupil G, Díaz FA (2003) Community-acquired pneumonia requiring hospitalization in immunocompetent elderly patients: clinical features, prognostic factors and treatment. Arch Bronconeumol 39:333–340CrossRefGoogle Scholar
  19. 19.
    Cascini S, Agabiti N, Incalzi RA, Pinnarelli L, Mayer F, Arcà M et al (2013) Pneumonia burden in elderly patients: a classification algorithm using administrative data. BMC Infect Dis 25:13.  https://doi.org/10.1186/1471-2334-13-559 CrossRefGoogle Scholar
  20. 20.
    Petersen PT, Egelund GB, Jensen AV, Andersen SB, Pedersen MF, Rohde G et al (2018) Associations between biomarkers at discharge and co-morbidities and risk of readmission after community-acquired pneumonia: a retrospective cohort study. Eur J Clin Microbiol Infect Dis 29(37):1103–1111.  https://doi.org/10.1007/s10096-018-3224-8 CrossRefGoogle Scholar
  21. 21.
    Viasus D, Del Rio-Pertuz G, Simonetti AF, Garcia-Vidal C, Acosta-Reyes J, Garavito A et al (2016) Biomarkers for predicting short-term mortality in community-acquired pneumonia: A systematic review and meta-analysis. J Infect 1(72):273–282.  https://doi.org/10.1016/j.jinf.2016.01.002 CrossRefGoogle Scholar
  22. 22.
    Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR et al (2007) Understanding the inflammatory cytokine response in pneumonia and sepsis. Arch Intern Med 13(167):1655.  https://doi.org/10.1001/archinte.167.15.1655 CrossRefGoogle Scholar
  23. 23.
    Hack CE, Hart M, Van Schijndel RJMS, Eerenberg AJM, Nuijens JH, Thijs LG et al (1992) Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 60:2835–2842PubMedPubMedCentralGoogle Scholar
  24. 24.
    Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W et al (1990) New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 69:307–316CrossRefGoogle Scholar
  25. 25.
    von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61:344–349.  https://doi.org/10.1016/j.jclinepi.2007.11.008 CrossRefGoogle Scholar
  26. 26.
    Simera I, Moher D, Hoey J, Schulz KF, Altman DG (2010) A catalogue of reporting guidelines for health research. Eur J Clin Investig 40:35–53.  https://doi.org/10.1111/j.1365-2362.2009.02234.x CrossRefGoogle Scholar
  27. 27.
    Martín-Salvador A, Torres-Sánchez I, Sáez-Roca G, López-Torres I, Rodríguez-Alzueta E, Valenza MC (2015) Age group analysis of psychological, physical and functional deterioration in patients hospitalized for pneumonia. Arch Bronconeumol (English Ed) 1(51):496–501.  https://doi.org/10.1016/j.arbr.2015.06.002 CrossRefGoogle Scholar
  28. 28.
    Calle A, Márquez MA, Arellano M, Pérez LM, Pi-Figueras M, Miralles R (2014) Geriatric assessment and prognostic factors of mortality in very elderly patients with community-acquired pneumonia. Arch Bronconeumol:11.  https://doi.org/10.1016/j.arbres.2014.01.012 CrossRefGoogle Scholar
  29. 29.
    Martín-Sánchez FJ, del Castillo JG (2015) Geriatric assessment: a key tool in the initial management of the elderly patient with community-acquired pneumonia. Arch Bronconeumol (English Ed) 1(51):523.  https://doi.org/10.1016/j.arbr.2015.07.011 CrossRefGoogle Scholar
  30. 30.
    Bordon J, Wiemken T, Peyrani P, Paz ML, Gnoni M, Cabral P, et al. Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 2010 1;138:279–83. doi:  https://doi.org/10.1378/chest.09-2702 CrossRefGoogle Scholar
  31. 31.
    Yende S, D’Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am. J. Respir. Crit. Care Med. 2008 1;177:1242–7. doi:  https://doi.org/10.1164/rccm.200712-1777OC CrossRefGoogle Scholar
  32. 32.
    Zhou J, Ren L, Chen D, Lin X, Huang S, Yin Y, et al. IL-17B is elevated in patients with pneumonia and mediates IL-8 production in bronchial epithelial cells. Clin. Immunol. 2017 1;175:91–8. doi:  https://doi.org/10.1016/j.clim.2016.12.008 CrossRefGoogle Scholar
  33. 33.
    Zobel K, Martus P, Pletz MW, Ewig S, Prediger M, Welte T et al (2012) Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. BMC Pulm Med 12:6.  https://doi.org/10.1186/1471-2466-12-6 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    van Vught LA, Endeman H, Meijvis SC, Zwinderman AH, Scicluna BP, Biesma DH et al (2014) The effect of age on the systemic inflammatory response in patients with community-acquired pneumonia. Clin Microbiol Infect 1(20):1183–1188.  https://doi.org/10.1111/1469-0691.12717 CrossRefGoogle Scholar
  35. 35.
    Rink L, Cakman I, Kirchner H (1998) Altered cytokine production in the elderly. Mech Ageing Dev 15(102):199–209CrossRefGoogle Scholar
  36. 36.
    Chen Z, Shao X, Dou X, Zhang X, Wang Y, Zhu C et al (2016) Role of the mycoplasma pneumoniae/Interleukin-8/Neutrophil Axis in the pathogenesis of pneumonia. PLoS One 11(11):e0146377.  https://doi.org/10.1371/journal.pone.0146377 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    San Jose ME, Ferreiro L, Soneira ME, Gonzalez-Barcala FJ, Vazquez MC, Golpe A et al (2014) Utility of measurement of Interleukin-1ß and interleukin-8 in the diagnosis of complicated parapneumonic pleural effusions. Am J Clin Pathol 1(142):467–473.  https://doi.org/10.1309/AJCPDC7PS8TIPBXP CrossRefGoogle Scholar
  38. 38.
    Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 23(29):71–109.  https://doi.org/10.1146/annurev-immunol-031210-101312 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineAlicante General University Hospital and the Institute for Health and Biomedical Research of Alicante (ISABIAL-Fundación FISABIO)AlicanteSpain
  2. 2.Department of Clinical MedicineUniversity Miguel Hernández de Elche. Campus of San Joan d’AlacantAlicanteSpain
  3. 3.Infectious Diseases UnitAlicante General University Hospital and the Institute for Health and Biomedical Research of Alicante (ISABIAL-Fundación FISABIO)AlicanteSpain
  4. 4.Department of History of Science and DocumentationUniversity of ValenciaValenciaSpain

Personalised recommendations